PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 669.50
Bid: 668.50
Ask: 670.00
Change: -0.50 (-0.07%)
Spread: 1.50 (0.224%)
Open: 673.00
High: 674.50
Low: 668.00
Prev. Close: 670.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Alliance with McNeil Nutritionals

13 Feb 2014 07:00

13 February 2014 – Tate & Lyle PLC

New Alliance with McNeil Nutritionals

Tate & Lyle PLC announces today the latest phase of its 30-year Sucralose partnership with McNeil Nutritionals, LLC through the establishment of a renewed SPLENDA® Alliance. The focus for the renewed partnership will be the development and growth of the global market for Sucralose and the SPLENDA® Brand. This is a natural evolution of the long-term partnership that has nurtured the success of Sucralose and the SPLENDA® Brand, following the strategic realignment announced in 2004. At that time, Tate & Lyle took over McNeil Nutritionals’ Sucralose manufacturing assets and responsibility for worldwide food and beverage ingredient sales, while McNeil Nutritionals, LLC retained ownership of the SPLENDA® Brand and the retail and food service business.

Both companies will partner on the continued development and promotion of the SPLENDA® Brand and Sucralose, including ingredient and brand protection initiatives. The new arrangements include terms for ongoing supply upon expiration of the current agreement. The partnership will continue to leverage the strengths of each company and ensure the continued growth of the SPLENDA® Sucralose business and the SPLENDA® Brand globally.

Javed Ahmed, Chief Executive of Tate & Lyle, said:

“We are delighted about the continuation of our established 30-year partnership with McNeil Nutritionals and look forward to the next phase of the relationship. Alongside our global partners, we are committed to growing the global market for SPLENDA® Sucralose, which remains the high intensity sweetener of choice due to its superior taste profile and stability, enabling its use across a broad range of applications. Together, we will continue to ensure that the SPLENDA® Brand remains the benchmark within the industry for quality, reliability and innovation well into the future.”

END

Notes to editors: selected historical background relating to SPLENDA® Sucralose based on previous disclosures

1976 Discovery of sucralose by Tate & Lyle and Queen Elizabeth's College, University of London researchers

1980 First agreements between Tate & Lyle and Johnson & Johnson. These were patent licences creating exclusive geographical territories for the two companies – for Johnson & Johnson, North America (excluding Canada), South America, the Caribbean, the Middle East and Australasia; for Tate & Lyle, Europe, Canada, Africa and Asia

1991 First approval granted for sucralose (Canada)

1998 US FDA approval for sucralose obtained

2000 McNeil's McIntosh plant, the world’s first integrated sucralose production facility, mechanically complete

2001 Global Sucralose Alliance announced, providing for the realignment of Tate & Lyle and McNeil sucralose activities. Under the realigned arrangements, Tate & Lyle to act as exclusive broker for sucralose ingredient sales in certain key markets; McNeil to market SPLENDA® Brand tabletop products exclusively

2003 EU approval for sucralose

2004 Further Sucralose realignment with Tate & Lyle becoming the sole manufacturer and responsible for worldwide ingredient sales of SPLENDA® Sucralose to food and beverage manufacturers and McNeil responsible for the worldwide SPLENDA® Brand retail and food service business. As part of the realignment, Tate & Lyle acquired McNeil’s sucralose manufacturing plant and other ingredient business assets for £71 million

The realignment included arrangements by which each company would participate in the success of the other. In the case of Tate & Lyle, deferred consideration was payable to McNeil for the first five years dependent on Tate & Lyle’s sucralose ingredient sales (above a target level). Tate & Lyle in turn received payments from McNeil based on McNeil sales of sucralose tabletop products for 10 years from the date of completion of the transaction. The aggregate amount paid to McNeil over the five years by Tate & Lyle amounted to £37 million. Assuming receipt of the £7 million payment anticipated in respect of the year ending 31 March 2014, the final such payment, the aggregate of the payments received from McNeil will amount to £75 million

2014 New SPLENDA® Alliance announced

For more information contact Tate & Lyle PLC:

Mathew Wootton, Group VP, Investor and Media RelationsTel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7500 100 320

Andrew Lorenz (FTI Consulting), Media RelationsTel: +44 (0) 20 7269 7113 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, operating from over 30 production facilities around the world.

Tate & Lyle operates through two global business units, Speciality Food Ingredients and Bulk Ingredients, supported by the Innovation and Commercial Development group. The Group's strategy is to become the leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our food systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2013, Tate & Lyle sales totalled £3.3 billion. http://www.tateandlyle.com.

SPLENDA® is a trademark of McNeil Nutritionals, LLC.

Copyright Business Wire 2014

Date   Source Headline
18th Nov 20214:15 pmRNSHolding(s) in Company
5th Nov 202111:45 amRNSDirector/PDMR Shareholding
4th Nov 20217:00 amRNSHalf-year Report
3rd Nov 20216:01 pmRNSDirectorate Change
29th Oct 202111:15 amRNSHolding(s) in Company
21st Oct 20214:45 pmRNSRestatement re Primary Products Disposal
18th Oct 20212:30 pmRNSHolding(s) in Company
13th Oct 202112:30 pmRNSHolding(s) in Company
6th Oct 20213:30 pmRNSHolding(s) in Company
6th Oct 202111:15 amRNSDirector/PDMR Shareholding
4th Oct 20212:30 pmRNSDirector/PDMR Shareholding
4th Oct 20217:00 amRNSTotal Voting Rights
30th Sep 202112:00 pmRNSResult of General Meeting
13th Sep 20214:30 pmRNSCircular re. KPS Partnership
1st Sep 20219:58 amRNSTotal Voting Rights
18th Aug 202110:10 amRNSDirector/PDMR Shareholding
11th Aug 20214:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20213:15 pmRNSTotal Voting Rights
29th Jul 202112:45 pmRNSResult of AGM
23rd Jul 20215:00 pmRNSHolding(s) in Company
22nd Jul 20213:15 pmRNSDirector/PDMR Shareholding
16th Jul 20213:30 pmRNSHolding(s) in Company
12th Jul 20214:00 pmRNSHolding(s) in Company
12th Jul 20213:50 pmRNSHolding(s) in Company
12th Jul 20217:00 amRNSTate & Lyle to be re-positioned as growth business
8th Jul 20213:30 pmRNSHolding(s) in Company
8th Jul 20213:14 pmRNSHolding(s) in Company
1st Jul 20214:40 pmRNSBlock listing Interim Review
1st Jul 20214:38 pmRNSTotal Voting Rights
15th Jun 20212:15 pmRNSAnnual Financial Report
14th Jun 20212:05 pmRNSHolding(s) in Company
14th Jun 20212:00 pmRNSHolding(s) in Company
9th Jun 20213:49 pmRNSDirector/PDMR Shareholding
1st Jun 20212:34 pmRNSTotal Voting Rights
27th May 20217:00 amRNSFinal Results
4th May 202111:30 amRNSTotal Voting Rights
28th Apr 202110:00 amRNSDirectorate Change
26th Apr 20217:00 amRNSResponse to media speculation
13th Apr 20213:45 pmRNSHolding(s) in Company
1st Apr 202112:00 pmRNSTotal Voting Rights
25th Mar 202110:00 amRNSDirectorate Changes
23rd Mar 20213:00 pmRNSHolding(s) in Company
12th Mar 202111:00 amRNSDirector Declaration
1st Mar 202111:00 amRNSTotal Voting Rights
26th Feb 202111:00 amRNSDirector Declaration
15th Feb 20214:43 pmRNSHolding(s) in Company
15th Feb 20214:40 pmRNSHolding(s) in Company
15th Feb 20214:37 pmRNSHolding(s) in Company
10th Feb 202111:15 amRNSAcquisition
28th Jan 20217:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.